A breakthrough in transdermal drug delivery.
Cost Hurdles Can Keep Patients From Accessing GLP-1 Receptor Agonists
ANAHEIM, Calif. — Insurance coverage and out-of-pocket costs for GLP-1 receptor agonists pose serious barriers to patients prescribed these drugs for type 2 diabetes and